Investigational drug · Phase 2
Shigella4V2
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Shigellosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "Shigella4V2"
First trial start
2024
Nov 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Shigella4V2", any sponsor or status.
Conditions studied
As listed on its trial records.
- Shigellosis
Largest trials
Live from ClinicalTrials.gov: studies naming "Shigella4V2" as an intervention, largest first.
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.Pivotal-lookingCompleted
LimmaTech Biologics AGIndustry
NCT06523231 · 110 participants · Start Apr 7, 2025 · Primary completion Aug 27, 2025
Drug: Shigella4V2; MenACWY · For: Shigellosis
Sites: Kisumu, Kenya
- A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineCompleted
LimmaTech Biologics AGIndustry
NCT06615375 · 97 participants · Start Nov 12, 2024 · Primary completion Apr 14, 2026
Drug: Shigella4V2; Placebo · For: Shigellosis
Sites: Atlanta, Georgia; Baltimore, Maryland; Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Shigellosis
- MenACWYPhase 22 trials
LimmaTech Biologics AG · Shigellosis, Salmonella Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.